Colorectal Cancer study is now starting recruitment! Click for more details

Breast Cancer study is still under recruitment! Click for more details.

Manuscript acceptance: Title "Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma" has bee accepted for publication in Journal of Hepatology (IF=26.8)

HnH CTC becomes a strategic partner with AstraZeneca! Click for more details.

Nonalcoholic Steatohepatitis (NASH) study is now starting recruitment! COMPLETED

New Gastric Cancer study started recruitment!! COMPLETED

Non-Small-Cell Lung Cancer with KRAS G12C mutation (previously treated) - COMPLETED

Gastrointestinal stroma tumors (previously treated with Imatinib) - COMPLETED

KRAS G12C mutation colorectal cancer (previously treated) -COMPLETED

Phase III Study Advanced Colorectal Cancer with KRAS G12C Mutation (COMPLETED)

Phase III Study of Second Generation ALK Inhibitors for ALK positive NSCLC (Closed)

Phase III Study of Immunotherapy for non-EGFR or ALK genomic tumor aberrations NSCLC (CLOSED)

COVID-19 and Clinical Trials at H&H Clinical Trial Centre description

Phase III Study of Immunotherapy for Locoregional Hepatocellular Carcinoma (CLOSED)

Phase III Study of Immunotherapy & Chemotherapy Combination for Advanced Biliary Tract Cancer (CLOSED)

Phase III Study of Monoclonal Antibody Therapy for Idiopathic Pulmonary Fibrosis (CLOSED)

Phase III Study of Immunotherapy for Hepatocellular Carcinoma (CLOSED)

Phase III Study of Target Therapy for Advanced Hepatocellular Carcinoma (CLOSED)

Phase III Study for Unresectable Hepatocellular Carcinoma - RECRUITING! (CLOSED)